Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 290

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Testosterone in women—the clinical significance

Davis, Susan R, Wahlin-Jacobsen, Sarah·2015·The Lancet Diabetes & Endocrinology
DOI 10.1016/s2213-8587(15)00284-3
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(15)00284-3

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 88

  1. Simpson, 2001, Minireview: aromatase and the regulation of estrogen biosynthesis—some new perspectives, Endocrinology, 142, 4589, 10.1210/endo.142.11.8547 · DOI · Paper page
  2. Wahlin-Jacobsen, 2015, Is there a correlation between androgens and sexual desire in women?, J Sex Med, 2, 358, 10.1111/jsm.12774 · DOI
  3. Randolph, 2015, Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition, J Clin Endocrinol Metab, 100, 258, 10.1210/jc.2014-1725 · DOI
  4. Davis, 2011, Clinical review: DHEA replacement for postmenopausal women, J Clin Endocrinol Metab, 96, 1642, 10.1210/jc.2010-2888 · DOI
  5. Rothman, 2011, Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry, Steroids, 76, 177, 10.1016/j.steroids.2010.10.010 · DOI · Paper page
  6. Bungum, 2013, The circadian variation in Anti-Müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women, PLoS One, 8, e68223, 10.1371/journal.pone.0068223 · DOI
  7. Burger, 2000, A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition, J Clin Endocrinol Metab, 85, 2832
  8. Harwood, 2009, Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization, Clin Chim Acta, 409, 78, 10.1016/j.cca.2009.09.003 · DOI
  9. Davis, 2005, Circulating androgen levels and self-reported sexual function in women, JAMA, 294, 91, 10.1001/jama.294.1.91 · DOI · Paper page
  10. Basson, 2010, Role of androgens in women's sexual dysfunction, Menopause, 17, 962, 10.1097/gme.0b013e3181d59765 · DOI
  11. Elraiyah, 2014, Clinical review: The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis, J Clin Endocrinol Metab, 99, 3543, 10.1210/jc.2014-2262 · DOI
  12. Davis, 2008, Testosterone for low libido in postmenopausal women not taking estrogen, N Engl J Med, 359, 2005, 10.1056/NEJMoa0707302 · DOI · Paper page
  13. Somboonporn, 2005, Testosterone for peri- and postmenopausal women, Cochrane Database Syst Rev, 4, 10.1002/14651858.CD004509.pub2 · DOI
  14. Baldassarre, 2013, Androgen receptor expression in the human vagina under different physiological and treatment conditions, Int J Impot Res, 25, 7, 10.1038/ijir.2012.25 · DOI
  15. Berman, 2003, Correlation of androgen receptors, aromatase, and 5-alpha reductase in the human vagina with menopausal status, Fertil Steril, 79, 925, 10.1016/S0015-0282(02)04923-3 · DOI
  16. Salinger, 1950, Proliferative effect of testosterone propionate on human vaginal epithelium, Acta Endocrinol (Copenh), 4, 265, 10.1530/acta.0.0040265 · DOI
  17. Raghunandan, 2010, A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women, J Sex Med, 7, 1284, 10.1111/j.1743-6109.2009.01667.x · DOI
  18. Fernandes, 2014, Efficacy of vaginally applied estrogen, testosterone, or polyacrylic acid on sexual function in postmenopausal women: a randomized controlled trial, J Sex Med, 11, 1262, 10.1111/jsm.12473 · DOI
  19. Witherby, 2011, Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study, Oncologist, 16, 424, 10.1634/theoncologist.2010-0435 · DOI
  20. Spoletini, 2014, Androgens and cardiovascular disease in postmenopausal women: a systematic review, Climacteric, 17, 625, 10.3109/13697137.2014.887669 · DOI
  21. Jones, 2004, The influence of testosterone upon vascular reactivity, Eur J Endocrinol, 151, 29, 10.1530/eje.0.1510029 · DOI
  22. Worboys, 2001, Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen, J Clin Endocrinol Metab, 86, 158, 10.1210/jcem.86.1.7103 · DOI
  23. Montalcini, 2007, Endogenous testosterone and endothelial function in postmenopausal women, Coron Artery Dis, 18, 9, 10.1097/01.mca.0000236290.79306.d1 · DOI
  24. Navarro-Dorado, 2008, Mechanisms involved in testosterone-induced vasodilatation in pig prostatic small arteries, Life Sci, 83, 569, 10.1016/j.lfs.2008.08.009 · DOI
  25. Maggio, 2012, The relationship between sex hormones, sex hormone binding globulin and peripheral artery disease in older persons, Atherosclerosis, 225, 469, 10.1016/j.atherosclerosis.2012.09.014 · DOI · Paper page
  26. Bernini, 1999, Endogenous androgens and carotid intimal-medial thickness in women, J Clin Endocrinol Metab, 84, 2008, 10.1210/jcem.84.6.5824 · DOI
  27. Golden, 2002, Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort, Am J Epidemiol, 155, 437, 10.1093/aje/155.5.437 · DOI
  28. Ouyang, 2009, Sex hormone levels and subclinical atherosclerosis in postmenopausal women: the Multi-Ethnic Study of Atherosclerosis, Atherosclerosis, 204, 255, 10.1016/j.atherosclerosis.2008.08.037 · DOI
  29. Calderon-Margalit, 2010, Prospective association of serum androgens and sex hormone-binding globulin with subclinical cardiovascular disease in young adult women: the “Coronary Artery Risk Development in Young Adults” women's study, J Clin Endocrinol Metab, 95, 4424, 10.1210/jc.2009-2643 · DOI
  30. Debing, 2007, Endogenous sex hormone levels in postmenopausal women undergoing carotid artery endarterectomy, Eur J Endocrinol, 156, 687, 10.1530/EJE-06-0702 · DOI
  31. Naessen, 2010, Endogenous steroids measured by high-specificity liquid chromatography-tandem mass spectrometry and prevalent cardiovascular disease in 70-year-old men and women, J Clin Endocrinol Metab, 95, 1889, 10.1210/jc.2009-1722 · DOI
  32. Sievers, 2010, Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care patients, Eur J Endocrinol, 163, 699, 10.1530/EJE-10-0307 · DOI
  33. Laughlin, 2010, Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women, J Clin Endocrinol Metab, 95, 740, 10.1210/jc.2009-1693 · DOI
  34. Scarabin-Carré, 2012, High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort study, J Am Heart Assoc, 1, e001388, 10.1161/JAHA.112.001388 · DOI
  35. Benn, 2015, Extreme concentrations of endogenous sex hormones, ischemic heart disease, and death in women, Arterioscler Thromb Vasc Biol, 35, 471, 10.1161/ATVBAHA.114.304821 · DOI
  36. Ding, 2009, Sex hormone-binding globulin and risk of type 2 diabetes in women and men, N Engl J Med, 361, 1152, 10.1056/NEJMoa0804381 · DOI · Paper page
  37. Peter, 2010, Relationships of circulating sex hormone-binding globulin with metabolic traits in humans, Diabetes, 59, 3167, 10.2337/db10-0179 · DOI
  38. Davis, 2012, The contribution of SHBG to the variation in HOMA-IR is not dependent on endogenous oestrogen or androgen levels in postmenopausal women, Clin Endocrinol (Oxf), 77, 541, 10.1111/j.1365-2265.2011.04301.x · DOI
  39. Worsley, 2013, Endogenous estrogen and androgen levels are not independent predictors of lipid levels in postmenopausal women, Menopause, 20, 640, 10.1097/GME.0b013e318279bd4a · DOI
  40. Janssen, 2010, Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study, Obesity (Silver Spring), 18, 604, 10.1038/oby.2009.251 · DOI
  41. Pugeat, 2010, Sex hormone-binding globulin gene expression in the liver: drugs and the metabolic syndrome, Mol Cell Endocrinol, 316, 53, 10.1016/j.mce.2009.09.020 · DOI
  42. Golden, 2004, Glucose and insulin components of the metabolic syndrome are associated with hyperandrogenism in postmenopausal women: the atherosclerosis risk in communities study, Am J Epidemiol, 160, 540, 10.1093/aje/kwh250 · DOI
  43. Sutton-Tyrrell, 2005, Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN), Circulation, 111, 1242, 10.1161/01.CIR.0000157697.54255.CE · DOI · Paper page
  44. Davis, 2008, Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial, Ann Intern Med, 148, 569, 10.7326/0003-4819-148-8-200804150-00001 · DOI
  45. Iellamo, 2010, Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study, J Am Coll Cardiol, 56, 1310, 10.1016/j.jacc.2010.03.090 · DOI
  46. Brown, 2010, Production of proinflammatory cytokines and chemokines during neuroinflammation: novel roles for estrogen receptors alpha and beta, Endocrinology, 151, 4916, 10.1210/en.2010-0371 · DOI
  47. Bixo, 1995, Estradiol and testosterone in specific regions of the human female brain in different endocrine states, J Steroid Biochem Mol Biol, 55, 297, 10.1016/0960-0760(95)00179-4 · DOI
  48. Pike, 2009, Protective actions of sex steroid hormones in Alzheimer's disease, Front Neuroendocrinol, 30, 239, 10.1016/j.yfrne.2009.04.015 · DOI · Paper page
  49. Aleman, 2004, A single administration of testosterone improves visuospatial ability in young women, Psychoneuroendocrinology, 29, 612, 10.1016/S0306-4530(03)00089-1 · DOI
  50. Postma, 2000, Effects of testosterone administration on selective aspects of object-location memory in healthy young women, Psychoneuroendocrinology, 25, 563, 10.1016/S0306-4530(00)00010-X · DOI
  51. Wolf, 2002, Endogenous estradiol and testosterone levels are associated with cognitive performance in older women and men, Horm Behav, 41, 259, 10.1006/hbeh.2002.1770 · DOI · Paper page
  52. Flöter, 2000, Administration of testosterone undecanoate in postmenopausal women: effects on androgens, estradiol, and gonadotrophins, Menopause, 7, 251, 10.1097/00042192-200007040-00007 · DOI
  53. Kocoska-Maras, 2011, A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women, Fertil Steril, 95, 152, 10.1016/j.fertnstert.2010.05.062 · DOI
  54. Möller, 2010, Effects of testosterone and estrogen replacement on memory function, Menopause, 17, 983, 10.1097/gme.0b013e3181dc2e40 · DOI
  55. Davis, 2014, Effects of testosterone on visuospatial function and verbal fluency in postmenopausal women: results from a functional magnetic resonance imaging pilot study, Menopause, 21, 410, 10.1097/GME.0b013e3182a065ed · DOI
  56. Davison, 2013, Continuous-combined oral estradiol/drospirenone has no detrimental effect on cognitive performance and improves estrogen deficiency symptoms in early postmenopausal women: a randomized placebo-controlled trial, Menopause, 20, 1020, 10.1097/GME.0b013e318287474f · DOI
  57. Davis, 2014, Transdermal testosterone improves verbal learning and memory in postmenopausal women not on oestrogen therapy, Clin Endocrinol (Oxf), 81, 621, 10.1111/cen.12459 · DOI
  58. Shah, 2006, Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial, Menopause, 13, 600, 10.1097/01.gme.0000227333.50867.4e · DOI
  59. Clarke, 2009, Androgens and bone, Steroids, 74, 296, 10.1016/j.steroids.2008.10.003 · DOI
  60. Slemenda, 1996, Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women, J Clin Invest, 97, 14, 10.1172/JCI118382 · DOI · Paper page
  61. Rariy, 2011, Higher serum free testosterone concentration in older women is associated with greater bone mineral density, lean body mass, and total fat mass: the cardiovascular health study, J Clin Endocrinol Metab, 96, 989, 10.1210/jc.2010-0926 · DOI
  62. Lee, 2008, Associations of serum sex hormone-binding globulin and sex hormone concentrations with hip fracture risk in postmenopausal women, J Clin Endocrinol Metab, 93, 1796, 10.1210/jc.2007-2358 · DOI
  63. Davis, 1995, Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality, Maturitas, 21, 227, 10.1016/0378-5122(94)00898-H · DOI · Paper page
  64. Barrett-Connor, 1999, A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles, J Reprod Med, 44, 1012
  65. Watts, 1995, Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause, Obstet Gynecol, 85, 529, 10.1016/0029-7844(94)00448-M · DOI · Paper page
  66. Miller, 2006, Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study, J Clin Endocrinol Metab, 91, 1683, 10.1210/jc.2005-2596 · DOI
  67. Popat, 2014, Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement, J Clin Endocrinol Metab, 99, 3418, 10.1210/jc.2013-4145 · DOI
  68. Key, 2001, Epidemiology of breast cancer, Lancet Oncol, 2, 133, 10.1016/S1470-2045(00)00254-0 · DOI · Paper page
  69. Davis, 2011, Cardiovascular and cancer safety of testosterone in women, Curr Opin Endocrinol Diabetes Obes, 18, 198, 10.1097/MED.0b013e328344f449 · DOI
  70. Peters, 2009, Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer, Cancer Res, 69, 6131, 10.1158/0008-5472.CAN-09-0452 · DOI · Paper page
  71. Somboonporn, 2004, Testosterone effects on the breast: implications for testosterone therapy for women, Endocr Rev, 25, 374, 10.1210/er.2003-0016 · DOI
  72. Key, 2015, Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: reanalysis of 18 prospective studies, Steroids, 99, 49, 10.1016/j.steroids.2014.09.001 · DOI · Paper page
  73. Bulun, 2008, Aromatase expression in women's cancers, Adv Exp Med Biol, 630, 112, 10.1007/978-0-387-78818-0_8 · DOI
  74. Misso, 2005, Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy, Menopause, 12, 210, 10.1097/00042192-200512020-00016 · DOI
  75. Simpson, 2000, The role of local estrogen biosynthesis in males and females, Trends Endocrinol Metab, 11, 184, 10.1016/S1043-2760(00)00254-X · DOI · Paper page
  76. Tamimi, 2006, Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women, Arch Intern Med, 166, 1483, 10.1001/archinte.166.14.1483 · DOI
  77. Jick, 2009, Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer, Obstet Gynecol, 113, 74, 10.1097/AOG.0b013e31818fdde4 · DOI
  78. Ness, 2009, Influence of estrogen plus testosterone supplementation on breast cancer, Arch Intern Med, 169, 41, 10.1001/archinternmed.2008.507 · DOI
  79. Dimitrakakis, 2004, Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy, Menopause, 11, 531, 10.1097/01.GME.0000119983.48235.D3 · DOI
  80. Davis, 2009, The incidence of invasive breast cancer among women prescribed testosterone for low libido, J Sex Med, 6, 1850, 10.1111/j.1743-6109.2009.01289.x · DOI
  81. Glaser, 2013, Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study, Maturitas, 76, 342, 10.1016/j.maturitas.2013.08.002 · DOI
  82. White, 2012, A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder, Am Heart J, 163, 27, 10.1016/j.ahj.2011.09.021 · DOI
  83. Snabes, 2010, Low cardiovascular event rate in post-menopausal women with increased cardiac risk: initial findings from the ongoing blinded Libigel (testosterone gel) cardiovascular safety study, Endocr Rev, 31, S1299
  84. Ose, 2015, Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition, Int J Cancer, 136, 399, 10.1002/ijc.29000 · DOI
  85. Allen, 2008, Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC), Endocr Relat Cancer, 15, 485, 10.1677/ERC-07-0064 · DOI · Paper page
  86. Perrone, 2009, Effect of long-term testosterone administration on the endometrium of female-to-male (FtM) transsexuals, J Sex Med, 6, 3193, 10.1111/j.1743-6109.2009.01380.x · DOI
  87. Spark, 2005, Intrinsa fails to impress FDA advisory panel, Int J Impot Res, 17, 283, 10.1038/sj.ijir.3901308 · DOI
  88. Chen, 1996, The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders, Dermatology, 193, 177, 10.1159/000246242 · DOI

Cited by

See all 290

Metadata

Authors
Davis, S. R., & Wahlin-Jacobsen, S.
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2015-12
Volume
3
Issue
12
Pages
980-992
ISSN
2213-8587 (ISSN-L)
DOI
10.1016/s2213-8587(15)00284-3
OpenAlex
W1679218678
Cited by
290
References
13
FWCI
9.87
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
Australian National Health and Medical Research Council Research Fellow (grant number 1041853)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.